Literature DB >> 19059496

Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling.

Ibrahim Ince1, Saskia N de Wildt, Dick Tibboel, Meindert Danhof, Catherijne A J Knibbe.   

Abstract

Rational dosing guidelines for drugs in pediatrics are urgently needed. To develop these guidelines, we use population pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation by: (i) optimization of clinical trial designs based on preliminary data; (ii) development and internal validation of population PK-PD models using sparse data; (iii) external validation using independent data; and (iv) prospective clinical evaluation. Optimized dosing regimens for specific drugs may then serve as a basis to develop dosing guidelines for existing or newly developed drugs with similar disposition and/or effect. In addition to modeling of drug disposition (PK) pathways, we emphasize the need for modeling of effect (PD) pathways and the use of a multidisciplinary infrastructure for data-sharing.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19059496     DOI: 10.1016/j.drudis.2008.11.004

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  15 in total

1.  What is the right dose for children?

Authors:  Massimo Cella; Catherijne Knibbe; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2010-10       Impact factor: 4.335

Review 2.  The role of population PK-PD modelling in paediatric clinical research.

Authors:  Roosmarijn F W De Cock; Chiara Piana; Elke H J Krekels; Meindert Danhof; Karel Allegaert; Catherijne A J Knibbe
Journal:  Eur J Clin Pharmacol       Date:  2010-03-26       Impact factor: 2.953

3.  Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis.

Authors:  Esther J H Janssen; Diane E T Bastiaans; Pyry A J Välitalo; Annemarie M C van Rossum; Evelyne Jacqz-Aigrain; Hermione Lyall; Catherijne A J Knibbe; David M Burger
Journal:  Br J Clin Pharmacol       Date:  2017-02-14       Impact factor: 4.335

4.  External Evaluation of Population Pharmacokinetic Models of Vancomycin in Neonates: The transferability of published models to different clinical settings.

Authors:  Wei Zhao; Florentia Kaguelidou; Valérie Biran; Daolun Zhang; Karel Allegaert; Edmund V Capparelli; Nick Holford; Toshimi Kimura; Yoke-Lin Lo; José-Esteban Peris; Alison Thomson; John N van den Anker; May Fakhoury; Evelyne Jacqz-Aigrain
Journal:  Br J Clin Pharmacol       Date:  2013-04       Impact factor: 4.335

5.  Evidence-based morphine dosing for postoperative neonates and infants.

Authors:  Elke H J Krekels; Dick Tibboel; Saskia N de Wildt; Ilse Ceelie; Albert Dahan; Monique van Dijk; Meindert Danhof; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

6.  A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates.

Authors:  Roosmarijn F W De Cock; Karel Allegaert; Catherine M T Sherwin; Elisabet I Nielsen; Matthijs de Hoog; Johannes N van den Anker; Meindert Danhof; Catherijne A J Knibbe
Journal:  Pharm Res       Date:  2013-09-25       Impact factor: 4.200

7.  Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling.

Authors:  Esther J H Janssen; Pyry A J Välitalo; Karel Allegaert; Roosmarijn F W de Cock; Sinno H P Simons; Catherine M T Sherwin; Johan W Mouton; Johannes N van den Anker; Catherijne A J Knibbe
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

8.  Prospective Evaluation of a Model-Based Dosing Regimen for Amikacin in Preterm and Term Neonates in Clinical Practice.

Authors:  A Smits; R F W De Cock; K Allegaert; S Vanhaesebrouck; M Danhof; C A J Knibbe
Journal:  Antimicrob Agents Chemother       Date:  2015-07-27       Impact factor: 5.191

Review 9.  Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations.

Authors:  Ibrahim Ince; Catherijne A J Knibbe; Meindert Danhof; Saskia N de Wildt
Journal:  Clin Pharmacokinet       Date:  2013-05       Impact factor: 6.447

10.  Knowledge of developmental pharmacology and modeling approaches should be used to avoid useless trials in children.

Authors:  Saskia N de Wildt; Catherijne A J Knibbe
Journal:  Eur J Clin Pharmacol       Date:  2009-04-25       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.